Laurence Mallet-Legeai

Paris, 75015, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Dkk1 inhibition restores mandibular growth in an achondroplasia mouse model.

Dkk1 inhibition restores mandibular growth in an achondroplasia mouse model.

Journal: Biology open
Published: February 24, 2026

Response to letter to the editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".

Response to letter to the editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: October 08, 2025

Response to Letter to the Editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".

Response to Letter to the Editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: October 08, 2025

Fgfr3-Wnt signaling crosstalk is involved in maintaining cranial suture integrity.

Fgfr3-Wnt signaling crosstalk is involved in maintaining cranial suture integrity.

Journal: Bone research
Published: July 10, 2025

Utilizing CRISPR-Cas13d-knockdown in zebrafish to study a rare monogenic bone fragility syndrome.

Utilizing CRISPR-Cas13d-knockdown in zebrafish to study a rare monogenic bone fragility syndrome.

Journal: JBMR plus
Published: May 26, 2025

Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia.

Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: March 20, 2025

TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.

TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.

Journal: JCI insight
Published: November 15, 2024

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models.

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models.

Journal: Journal of visualized experiments : JoVE
Published: October 14, 2024

Foetal achondroplasia: Prenatal diagnosis, outcome and perspectives.

Foetal achondroplasia: Prenatal diagnosis, outcome and perspectives.

Journal: Journal of gynecology obstetrics and human reproduction
Published: July 16, 2024

FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia.

FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia.

Journal: Bone research
Published: June 15, 2024

Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model.

Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: November 10, 2023

Embryonic cranial cartilage defects in the Fgfr3Y367C /+ mouse model of achondroplasia.

Embryonic cranial cartilage defects in the Fgfr3Y367C /+ mouse model of achondroplasia.

Journal: Anatomical record (Hoboken, N.J. : 2007)
Published: April 12, 2023
Showing 1-12 of 45

Last Updated: 09/26/2026